US Patent

US11400067 — Pharmaceutical compositions and uses directed to lysosomal storage disorders

Method of Use · Assigned to Intrabio Ltd · Expires 2037-04-19 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating lysosomal storage disorders by administering acetyl-leucine or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Aqneursa (LEVACETYLLEUCINE) · Intrabio

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4170`	—	Aqneursa

Patent Metadata

Patent number: US11400067
Jurisdiction: US
Classification: Method of Use
Expires: 2037-04-19
Drug substance claim: No
Drug product claim: No
Assignee: Intrabio Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.